Asciminib is a targeted drug of several generations

Asciminib (Asciminib) is an allosteric inhibitor targeting the myristyl pocket of ABL1. It has been approved by the U.S. Food and Drug Administration (FDA)Approved for use in patients with chronic phase (CP) chronic myeloid leukemia (CML) resistant or intolerant to ≥ 2 patients with previous TKI or T315I mutations. Due to the development of effectiveBCR::ABL1 tyrosine kinase inhibitors (TKIs), the prognosis of CP-CML patients has improved significantly. However, approximately 15-20% of patients ultimately experience treatment failure due to resistance or intolerance to TKI therapy.

Because the prognosis of patients with multiple TKI failures is poor, an optimal therapeutic approach is needed to treat this disease. In a phase 1 trial, aceminib monotherapy showed a relatively favorable safety profile and effective efficacy in patients with and without the T315I mutation. In subsequent phase 3 clinical trials, aximinib treatment resulted in significantly higher major molecular response rates and lower discontinuation rates compared with bosutinib. Several clinical trials are ongoing in different clinical settings to evaluate aceminib as first-line treatment for newly diagnosed CP-CML.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminib currently sold overseas is very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.